Skip to main content

Health economic modeling for medical technologies in Europe

Early and comprehensive economic models to determine economic value proposition and inform healthcare decision-makers

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Health technology assessments initiated by the Agency for Health Technology Assessment and Tariff System (AOTMiT) in the fourth quarter of 2023 in Poland

06 Dec 2023

In the fourth quarter of 2023, two new health technology assessments were initiated by the Agency for Health Technology Assessment and Tariff System (AOTMiT). The assessments belong to the cardiovascular and neurovascular technology groups.

On November 21, 2023, the AOTMiT initiated the evaluation of the monitoring of cardiac activity and therapy of dangerous ventricular arrhythmias using a defibrillation vest within the preparation of the recommendation for the possible inclusion in the list of guaranteed services in the field of outpatient specialist care.

On the same day, the Agency initiated the evaluation of the treatment of the acute phase of ischemic stroke with transcatheter mechanical thrombectomy of intracerebral or intracranial vessels within the preparation of recommendations on the validity of qualifications for the provision of this healthcare service. On November 29, 2023, the position of the Transparency Council was published, in which it was outlined that the Council considers it justified to qualify the above-mentioned healthcare service as a guaranteed service in the field of hospital treatment.

The AOTMiT is a consultative and advisory entity supervised by the Minister of Health (MoH). The role of the Agency is to assist the MoH in the decision-making process with regard to the financing of medicines and medical technologies in the healthcare system.

The full details in Polish can be found here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.